Literature DB >> 18436192

Antagonist-radioligand binding to D2L-receptors in intact cells.

Ann Packeu1, Jean-Paul De Backer, Isabelle Van Liefde, Patrick M L Vanderheyden, Georges Vauquelin.   

Abstract

D(2)-dopamine receptors mediate most of the physiological actions of dopamine and are important recognition sites for antipsychotic drugs. Earlier binding studies were predominantly done with broken cell preparations with the tritiated D(2)-receptor antagonists [(3)H]-raclopride, a hydrophilic benzamide, and [(3)H]-spiperone, a highly hydrophobic butyrophenone. Here we compared [(3)H]-raclopride and [(3)H]-spiperone binding properties in intact Chinese Hamster Ovary cells stably expressing recombinant human D(2L)-receptors. Specific binding of both radioligands occurred to a comparable number of sites. In contrast to the rapid dissociation of [(3)H]-raclopride in both medium only and in the presence of an excess of unlabelled ligand [(3)H]-spiperone dissociation was only observed in the latter condition, and it was still slower than in broken cell preparations. However, this could not explain the pronounced difference in the potency of some unlabelled ligands to compete with both radioligands. To integrate these new findings, a model is proposed in which raclopride approaches the receptor from the aqueous phase, while spiperone approaches the receptor by lateral diffusion within the membrane.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436192     DOI: 10.1016/j.bcp.2008.03.001

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 3.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 4.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

5.  Characterization of 12 GnRH peptide agonists - a kinetic perspective.

Authors:  Indira Nederpelt; Victoria Georgi; Felix Schiele; Katrin Nowak-Reppel; Amaury E Fernández-Montalván; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2015-11-04       Impact factor: 8.739

Review 6.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

7.  Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol.

Authors:  A Szczuka; M Wennerberg; A Packeu; G Vauquelin
Journal:  Br J Pharmacol       Date:  2009-07-07       Impact factor: 8.739

Review 8.  Ligands, their receptors and ... plasma membranes.

Authors:  G Vauquelin; A Packeu
Journal:  Mol Cell Endocrinol       Date:  2009-07-30       Impact factor: 4.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.